FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds selected from a group comprising 2,3,4,9-tetrahydro-1H-carbazoles of formula I
,
where R1, R2, R3 and R4 independently denote hydrogen, alkyl, alkoxy, halogen, nitro, cyano, trifluoromethyl or formyl, R5 denotes hydrogen, alkyl or -CF3, R6 denotes alkoxy, arylalkoxy, selected from benzyloxy and 1-phenylethoxy, or -NR7R8, R7 and R8 independently denote hydrogen, alkyl, cyanoalkyl, alkenyl, where alkenyl is ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl or 5-hexenyl; aryl, where aryl is a phenyl or naphthyl radical, where said radicals can optionally be monosubstituted with a halogen, alkyl, alkoxy, -CF3, -OCF3, phenylalkyl or phenylcarbonyl; or disubstituted with a substitute independently selected from halogen, alkoxy and phenyl; arylalkyl, where arylalkyl is phenylalkyl, where the alkyl group can optionally be substituted with phenyl; phenylalkyl, where the phenyl ring can optionally be substituted with methylenedioxy; phenylalkyl which is disubstituted with a halogen; phenylalkyl which is monosubstituted with a halogen, -CF3, -OCHF2, alkyl or alkylsulfanyl; or naphthylalkyl; phenylcarbonyl; cycloalkyl, where cycloalkyl is a cyclopentyl or cyclohexyl radical, where said radicals can optionally be substituted with a condensed benzene ring; pyridylalkyl; thienylalkyl; or R7 and R8 together with a nitrogen atom to which they are bonded form a heterocyclic 5-, 6-, 7- or 8-member ring system containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur atoms, wherein said cyclic system can optionally be substituted with (1) one or two condensed benzene rings, where the benzene rings are unsubstituted or substituted with one or two substitutes independently selected from a group comprising C1-C4alkyl, C1-C4alkoxy, halogen, -CF3 and -OCF3; (2) unsubstituted phenyl ring, (3) mono- or disubstituted phenyl ring, where the substitutes are independently selected from a group comprising halogen, C1-C4alkyl, C1-C4alkoxy, -CF3 and -OCF3; or (4) phenylalkyl, where the alkyl group is substituted with phenyl; where the term "alkyl", separately or in any combination, denotes a saturated straight or branched hydrocarbon chain containing 1-7 carbon atoms; where the said alkyl group is unsubstituted unless stated otherwise; or to pharmaceutically acceptable salts thereof. Invention also relates to a pharmaceutical composition and to use of compounds in claim 1.
EFFECT: obtaining novel biologically active compounds having CRTH2 receptor antagonist activity.
13 cl, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF INDOLE-1-YLACETIC ACID | 2005 |
|
RU2376286C2 |
PYRROLO- AND THIAZOLOPYRIDINE COMPOUNDS (VERSIONS) AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2461557C2 |
QUINOXALINES AND AZAQUINOXALINES AS CRTH RECEPTOR MODULATORS | 2011 |
|
RU2589709C2 |
GLUTAMATES AS AGGRECANASE INHIBITORS | 2006 |
|
RU2436768C2 |
HETEROBICYCLIC SULPHONAMIDE DERIVATIVES FOR TREATING DIABETES | 2007 |
|
RU2407740C2 |
HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM | 2007 |
|
RU2364597C1 |
TRICYCLIC SPIRO-DERIVATIVES AS CRTH2 MODULATORS | 2006 |
|
RU2478639C2 |
BIPHENYLSULFONYLCYANAMIDES, METHOD FOR THEIR PREPARING AND THEIR APPLYING AS DRUGS | 1999 |
|
RU2247111C2 |
PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | 2008 |
|
RU2490265C2 |
3-(HETEROARYLAMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF PROSTAGLANDIN D2 RECEPTORS | 2011 |
|
RU2562255C2 |
Authors
Dates
2010-11-20—Published
2005-12-22—Filed